Carl Zeiss Meditec
€31.30Change from previous close: +0.32%Absolute change: +€0.10
At a glance
- Revenue growth
- +7.82%
- FY to Sep 2025 vs FY to Sep 2024
- Net income growth
- −20.99%
- FY to Sep 2025 vs FY to Sep 2024
- Net margin
- 6.3%
- FY to Sep 2024: 8.7%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Total revenue | 467 | 628 | 550 | 560 |
| Cost of revenue | 240 | 296 | 260 | 258 |
| Gross profit | 227 | 332 | 290 | 302 |
| Selling, general and administrative | 151 | 170 | 154 | 154 |
| Research and development | 75.5 | 91.8 | 81.4 | 75.6 |
| Operating income | 1.0 | 71.1 | 53.1 | 71.2 |
| EBIT | 2.0 | 73.5 | 47.7 | 72.4 |
| EBITDA | 2.0 | 73.5 | 47.7 | 72.4 |
| Interest expense | 7.4 | 6.3 | 6.4 | 7.0 |
| Pre-tax income | -5.4 | 67.2 | 41.2 | 65.4 |
| Income tax | 0.2 | 13.0 | 13.5 | 19.8 |
| Net income | -4.9 | 51.8 | 28.4 | 45.3 |
| Net income to common shareholders | -4.9 | 51.8 | 28.4 | 45.3 |
| Basic EPS | -0.06 | — | — | 0.52 |
| Diluted EPS | -0.06 | — | — | 0.52 |
| Average shares (basic) | 81.7 | — | — | 87.2 |
| Average shares (diluted) | 81.7 | — | — | 87.2 |